Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways

Peptides

Volumn 22, Issue 6, 2001, Pages 879-886

  Rekasi, Zoltan ^a,b   Varga, Jozsef L ^a,b   Schally, Andrew V ^a,b   Plonowski, Artur ^a,b   Halmos, Gabor ^a,b   Csernus, Balazs ^a,b   Armatis, Patricia ^a   Groot, Kate ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer drugs; cAMP; GHRH antagonists; Signal transduction; Tumoral GHRH receptors

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; ANTINEOPLASTIC AGENT; CYCLIC AMP; FORSKOLIN; GROWTH HORMONE RELEASING FACTOR ANTAGONIST; GROWTH HORMONE RELEASING FACTOR RECEPTOR; IODINE 125; JV 138; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPOPHYSIS; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; XENOGRAFT;

ADENYLATE CYCLASE; ANIMALS; CELL DIVISION; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; GLUCAGON; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, NUDE; MUSCLES; NEOPLASM TRANSPLANTATION; NEUROPEPTIDES; PANCREATIC NEOPLASMS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RADIOIMMUNOASSAY; SECRETIN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

MUS MUSCULUS;

EID: 0035007344     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(01)00413-2     Document Type: Article

References (40)

1. Cyclic AMP induces transforming growth factor β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3
2. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit growth of OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice
3. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro
4. Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro
5. The dispersed cell superfusion system
6. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro
7. VIP and PACAP: Very important in pain?
8. Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines
9. Molecular and cell biology of the growth hormone-releasing hormone receptor
10. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone
11. Growth hormone releasing hormone stimulates cAMP release in superfused rat pituitary cells
12. Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3′,5′-monophosphate release in superfused rat pituitary cells
13. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone
14. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells
15. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of CAKI-I renal adenocarcinoma
16. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers
17. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice
18. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice
19. Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma
20. Antitumorigenic actions of growth hormone-releasing hormone antagonists
21. Growth hormone-releasing antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
22. Growth effects of regulatory peptides on human pancreatic cancer lines PANC-1 and MIA PaCa-2
23. Growth hormone-releasing hormone: Synthesis and signaling
24. Peptides and growth factors in non-small cell lung cancer
25. Adenylate cyclase activity in human pancreatic adenocarcinoma cell lines
26. Inhibition of human pancreatic cancer cell (MIA PaCa-2) growth by cholera toxin and 8-chloro-cAMP in vitro
27. Intracellular calcium stores are involved in growth hormone-releasing hormone signal transduction in rat somatotrophs
28. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone
29. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay
30. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers
31. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system
32. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancers
33. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro
34. Antagonistic analogs of growth hormone-releasing hormone (GHRH): New potential antitumor agents
35. Antagonists of growth hormone-releasing hormone (GHRH) decrease IGF-II production of HT-29 human colon cancer cells and inhibit tumor growth
36. Antagonists of growth hormone-releasing hormone (GHRH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors
37. Radiolabeled somatostatin analogs in prostate cancer
38. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
39. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone
40. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GHRH)